Antithrombin III in critically ill patients

British Medical Journal

Volumn 335, Issue 7632, 2007, Pages 1219-1220

  Torossian, A ^a   Graf, J ^b   Bauhofer, A ^c  

^a Department of Anaesthesia and Intensive Care Medicine ^*

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; HEPARIN;

ANTITHROMBIN DEFICIENCY; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL STUDY; CRITICALLY ILL PATIENT; DISEASE CLASSIFICATION; DOSE RESPONSE; EDITORIAL; INFECTION; INTERVENTION STUDY; PATIENT SELECTION; PREECLAMPSIA; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEPSIS; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTITHROMBIN III; CRITICAL ILLNESS; HEMORRHAGE; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 37749050913     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39399.552245.80     Document Type: Editorial

References (12)

1. Brinkhous KM, Smith HP Jr, Warner ED, Seegers WH. Heparin and blood clotting. Science 1939;90:539.
2. Corrigan JJ Jr, Ray WL, May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med 1968;279:851-6.
3. Leitner JM, Firbas C, May FB, Reiter RA, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther 2006;79:23-34.
4. Afshari A, Wetterslev J, Brok J, Møller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007; 335:1248-51.
5. Bellomo R, Bagshaw SM. Evidence-based medicine: classifying the evidence from clinical trials - the need to consider other dimensions. Crit Care 2006;10:232.
6. Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analysis. BMJ 2007;335:914.
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
8. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78.
9. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-7.
10. Aibiki M, Fukuoka N, Nisiyama T, Maekawa S, Shirakawa Y. Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmakokinetic study. Shock 2007;28:141-7.
11. Arndt C, Bauhofer A, Wulf H, Torossian A. Prophylaxis with heparin and granulocyte colony-stimulating factor (G-CSF) improves survival in septic rats. Anästhesiologie Intensivmedizin 2007;48:366.
12. James F, De La Rosa G, Arango C, Fortich F, Morales C, Aguirre D, et al. A randomized clinical trial of unfractioned heparin for treatment of sepsis (the HETRASE study): design and rationale NCT00100308. Trials 2006;7:19.